Inhibition of SREBP-2 activity in cell and mouse models of NAFLD upregulated expression of autophagic markers, ultimately reducing lipid deposition (Deng et al., 2017). The gene discussed is SREBF2; the disease is metabolic dysfunction-associated steatotic liver disease.